These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31908294)

  • 1. Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?
    Nuzzolese I; Montemurro F
    Lancet Oncol; 2020 Jan; 21(1):21-24. PubMed ID: 31908294
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer.
    Richardson LC; Wang W; Hartzema AG; Wagner S
    Breast J; 2007; 13(6):581-7. PubMed ID: 17983400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Taxanes in metastatic breast cancer. An analysis of a systematic Cochrane review].
    Nielsen DL; Kamby C
    Ugeskr Laeger; 2006 Sep; 168(37):3117-20. PubMed ID: 16999914
    [No Abstract]   [Full Text] [Related]  

  • 4. A systematic overview of chemotherapy effects in breast cancer.
    Bergh J; Jönsson PE; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.
    Wilcken N; Dear R
    Eur J Cancer; 2008 Oct; 44(15):2218-25. PubMed ID: 18722111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative adjuvant chemotherapy of breast cancer: the Scandinavian experience.
    Nissen-Meyer R; Host H; Kjellgren K; Mansson B; Norin T
    Recent Results Cancer Res; 1986; 103():95-102. PubMed ID: 3526478
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy: what progress in the last 5 years?
    Hamilton A; Hortobagyi G
    J Clin Oncol; 2005 Mar; 23(8):1760-75. PubMed ID: 15755984
    [No Abstract]   [Full Text] [Related]  

  • 8. RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer.
    O'Shaughnessy JA; Brufsky AM
    Clin Breast Cancer; 2008 Aug; 8(4):370-3. PubMed ID: 18757267
    [No Abstract]   [Full Text] [Related]  

  • 9. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review.
    Akl EA; Briel M; You JJ; Sun X; Johnston BC; Busse JW; Mulla S; Lamontagne F; Bassler D; Vera C; Alshurafa M; Katsios CM; Zhou Q; Cukierman-Yaffe T; Gangji A; Mills EJ; Walter SD; Cook DJ; Schünemann HJ; Altman DG; Guyatt GH
    BMJ; 2012 May; 344():e2809. PubMed ID: 22611167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer.
    Jones D; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2006 Jul; (3):CD003368. PubMed ID: 16856005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel for treatment of solid tumours: a systematic review of clinical data.
    Montero A; Fossella F; Hortobagyi G; Valero V
    Lancet Oncol; 2005 Apr; 6(4):229-39. PubMed ID: 15811618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary chemotherapy for breast cancer: the evidence and the future.
    Mano MS; Awada A
    Ann Oncol; 2004 Aug; 15(8):1161-71. PubMed ID: 15277254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum containing regimens for metastatic breast cancer.
    Carrick S; Ghersi D; Wilcken N; Simes J
    Cochrane Database Syst Rev; 2004; (3):CD003374. PubMed ID: 15266482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum containing regimens for metastatic breast cancer.
    Carrick S; Ghersi D; Wilcken N; Simes J
    Cochrane Database Syst Rev; 2004; (2):CD003374. PubMed ID: 15106201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Standard chemotherapy for metastatic breast cancer].
    Tashiro H
    Nihon Rinsho; 2000 Apr; 58 Suppl():246-53. PubMed ID: 11026002
    [No Abstract]   [Full Text] [Related]  

  • 17. [Overview of vinorelbine for metastatic breast cancer].
    Adachi I
    Nihon Rinsho; 2000 Apr; 58 Suppl():271-8. PubMed ID: 11026006
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab for advanced breast cancer: all tied up with a RIBBON?
    Burstein HJ
    J Clin Oncol; 2011 Apr; 29(10):1232-5. PubMed ID: 21383305
    [No Abstract]   [Full Text] [Related]  

  • 19. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose chemotherapy for breast cancer: is another look warranted?
    Nieto Y; Jones RB; Shpall EJ
    Curr Opin Oncol; 2004 Mar; 16(2):114-9. PubMed ID: 15075901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.